<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ecallantide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ecallantide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ecallantide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9035" href="/d/html/9035.html" rel="external">see "Ecallantide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11665" href="/d/html/11665.html" rel="external">see "Ecallantide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F9728482"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anaphylaxis has been reported after administration of ecallantide. Because of the risk of anaphylaxis, ecallantide should only be administered by a health care provider with appropriate medical support to manage anaphylaxis and hereditary angioedema. Health care providers should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema, and patients should be monitored closely. Do not administer ecallantide to patients with known clinical hypersensitivity to ecallantide.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9640246"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kalbitor</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F13735787"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Kallikrein Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F9728581"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eadc6bcc-1f3c-4d04-af5b-2569fb4b05d7">Hereditary angioedema, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema (HAE), treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 8 to &lt;12 years of age: Limited data available (Frank 2016): SubQ: 30 mg (as three 10 mg [1 mL] injections); dosing based on data pooled from 4 clinical studies (n=29, ages 9 to 17 years including 25 who received at least 1 dose of ecallantide) (MacGinnitie 2013) and a single case report in an 8-year-old (Dy 2013); efficacy was observed with no adverse events reported.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: SubQ: 30 mg (as three 10 mg [1 mL] injections); if attack persists, may repeat an additional 30 mg within 24 hours.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51107942"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51107943"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F9728582"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9035" href="/d/html/9035.html" rel="external">see "Ecallantide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6fdac7f-1466-435d-8ceb-b7b28141de63">Hereditary angioedema attacks, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema attacks, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Because of the risk of anaphylaxis, self-administration at home is not recommended; however, may be administered at home by a trained health care professional. Shortening the time between symptom onset and drug administration helps minimize morbidity and mortality (US HAEA [Busse 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 30 mg once, administered as three 10 mg (1 mL) injections into skin of the abdomen, upper arm, or thigh, ≥2 inches apart, and away from the location of angioedema; if attack persists after ≥1 hour, may repeat 1 additional 30 mg dose within 24 hours (Zuraw 2022; manufacturer's labeling).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991699"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989018"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F9728530"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (8% to 16%), fatigue (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (5% to 13%), diarrhea (4% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (IgE: 5% to 20%; neutralizing: 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (5%), skin rash (3%), urticaria (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (6%), upper abdominal pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (3% to 7%; includes bruising, erythema, irritation, pain, pruritus, urticaria)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (8%), nasopharyngitis (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction (chest discomfort, flushing, pharyngeal edema, rhinorrhea, sneezing, nasal congestion, throat irritation, wheezing, hypotension)</p></div>
<div class="block coi drugH1Div" id="F9728509"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ecallantide or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F9728528"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis have been reported. Reactions usually occur within 1 hour and may include chest discomfort, flushing, hypotension, nasal congestion, pharyngeal edema, pruritus, rash, rhinorrhea, sneezing, throat irritation, urticaria, and wheezing. Signs/symptoms of hypersensitivity reactions may be similar to those associated with hereditary angioedema attacks; therefore, consideration should be given to treatment methods; monitor patients closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunogenicity: Some patients may develop antibodies to ecallantide during therapy; seroconversion may increase the risk of hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: The role of ecallantide in the management of patients with ACEI-induced angioedema is controversial (Bernstein 2015; Lewis 2015).</p></div>
<div class="block foc drugH1Div" id="F9728587"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kalbitor: 10 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F9728504"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322780"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Kalbitor Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $6,648.44</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614447"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer only by a health care provider in presence of appropriate medical support to manage anaphylaxis and hereditary angioedema.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: SubQ: Administer as 3 (10 mg/mL each) injections subcutaneously into skin of abdomen, upper arm, or thigh (do not administer at site of attack). Recommended needle size is 27 gauge. Separate injections by 2 inches (5 cm). May inject all doses in same or different location; rotation of sites is not necessary. Do not self-administer. Monitor/observe for hypersensitivity.</p></div>
<div class="block adm drugH1Div" id="F9728584"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">SubQ: Administer as 3 (10 mg/mL each) injections subcutaneously into skin of abdomen, upper arm, or thigh (do not administer at site of attack). Recommended needle size is 27 gauge. Separate injections by 2 inches (5 cm). May inject all doses in same or different location; rotation of sites is not necessary. Monitor/observe for hypersensitivity. Should only be administered by a health care professional; not for self-administration.</p></div>
<div class="block sts drugH1Div" id="F9728558"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F). Protect from light. May be stored for up to 14 days at &lt;30°C (&lt;86°F).</p></div>
<div class="block meg drugH1Div" id="F9728483"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F125277s081lbl.pdf%23page%3D13&amp;token=0xArWZkun6glelWIj5kLrPsPagL6%2Buuo%2BwyAGz4qelnrm8%2F17fPXzper%2FSMtd%2FD8hDalPCkJv92UEuafxPvgMCumy6mDyE%2F%2FYdZz%2FAvya3Dc9h7pTboPDoqBwvgp7ve0&amp;TOPIC_ID=97557" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf#page=13</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53570845"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute attacks of hereditary angioedema (HAE) (FDA approved in ages ≥12 years and adults)</p></div>
<div class="block cyt drugH1Div" id="F13299247"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9922507"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F9728507"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">If treatment of acute attacks for hereditary angioedema (HAE) is needed during pregnancy, agents other than ecallantide are recommended. Patients with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (WAO/EAACI [Maurer 2022]).</p></div>
<div class="block mopp drugH1Div" id="F53570844"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity reaction</p></div>
<div class="block pha drugH1Div" id="F9728559"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ecallantide is a recombinant protein which inhibits the conversion of high molecular weight kininogen to bradykinin by selectively and reversibly inhibiting plasma kallikrein. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.</p></div>
<div class="block phk drugH1Div" id="F9728561"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: 30 minutes to 4 hours (Epstein 2008)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 26.4 ± 7.8 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2 ± 0.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58207669"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Kalbitor</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Kalbitor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kalbitor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25601538">
<a name="25601538"></a>Bernstein JA, Moellman JJ, Collins SP, Hart KW, Lindsell CJ. Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. <i>Ann Allergy Asthma Immunol</i>. 2015;114(3):245-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/25601538/pubmed" id="25601538" target="_blank">25601538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32898710">
<a name="32898710"></a>Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. <i>J Allergy Clin Immunol Pract</i>. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/32898710/pubmed" id="32898710" target="_blank">32898710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22197274">
<a name="22197274"></a>Caballero T, Farkas H, Bouillet L, et al. International Consensus and Practical Guidelines on the Gynecologic and Obstetric Management of Female Patients With Hereditary Angioedema Caused by C1 Inhibitor Deficiency. <i>J Allergy Clin Immunol</i>. 2012;129(2):308-320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/22197274/pubmed" id="22197274" target="_blank">22197274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23282420">
<a name="23282420"></a>Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. <i>World Allergy Organ J</i>. 2012;5(12):182-199. doi:10.1097/WOX.0b013e318279affa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/23282420/pubmed" id="23282420" target="_blank">23282420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23987203">
<a name="23987203"></a>Dy TB, Rasheed M, Parikh P, Bernstein L. Resolution of an acute attack of idiopathic angioedema with ecallantide.<i> Ann Allergy Asthma Immunol</i>. 2013; 111(3):224-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/23987203/pubmed" id="23987203" target="_blank">23987203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19093699">
<a name="19093699"></a>Epstein TG, Bernstein JA. Current and Emerging Management Options for Hereditary Angioedema in the US. <i>Drugs</i>. 2008;68(18):2561-2573.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/19093699/pubmed" id="19093699" target="_blank">19093699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27940765">
<a name="27940765"></a>Frank MM, Zuraw B, Banerji A, et al. Management of children with hereditary angioedema due to C1 inhibitor deficiency. <i>Pediatrics</i>. 2016;138(5). pii: e20160575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/27940765/pubmed" id="27940765" target="_blank">27940765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kalbitor.1">
<a name="Kalbitor.1"></a>Kalbitor (ecallantide) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182544">
<a name="25182544"></a>Lewis LM, Graffeo C, Crosley P, et al. Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial. <i>Ann Emerg Med</i>. 2015;65(2):204-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/25182544/pubmed" id="25182544" target="_blank">25182544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23878046">
<a name="23878046"></a>MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Use of ecallantide in pediatric hereditary angioedema. <i>Pediatrics</i>. 2013;132(2):e490-497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/23878046/pubmed" id="23878046" target="_blank">23878046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35497649">
<a name="35497649"></a>Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.<i> World Allergy Organ J</i>. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/35497649/pubmed" id="35497649" target="_blank">35497649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuraw.1">
<a name="Zuraw.1"></a>Zuraw B, Farkas H. Hereditary angioedema: acute treatment of angioedema attacks. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818886">
<a name="20818886"></a>Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. <i>N Engl J Med</i>. 2010;363(6):513-522. doi:10.1056/NEJMoa0805538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ecallantide-pediatric-drug-information/abstract-text/20818886/pubmed" id="20818886" target="_blank">20818886</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 97557 Version 63.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
